Drug combo for basal-like pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of three drugs (gemcitabine, erlotinib, and nab-paclitaxel) for people with a specific type of pancreatic cancer called 'basal-like' PDAC. It aims to see if this targeted approach works better than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of pancreatic cancer (adenocarcinoma) that is either locally advanced, borderline resectable, or has spread to other parts of the body.
- You may have received up to 2 cycles of standard chemotherapy (FOLFIRINOX or NALIRIFOX) before, but no other cancer treatments in the past 28 days.
- You must be willing to have a biopsy (tissue sample) if you don't already have one available from a previous procedure.
- You must be in generally good health, able to do daily activities with little to no help (ECOG performance status 0 or 1).
- If you have had brain metastases, they must be treated and stable, and you must be off steroids for at least 2 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
This trial tests a combination of four drugs (surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine) as a first treatment for people whose pancreatic cancer has spread to other parts of the body. The goal is to see if this combination helps shrink tumors and improve survival.
This trial studies NovoTTF-200T(P), a portable treatment device, combined with standard chemotherapy (gemcitabine and nab-paclitaxel) for people with resectable pancreatic adenocarcinoma. It aims to improve treatment results by trying this combination before surgery.
This trial tests a new drug (OMTX705) combined with standard chemotherapy (gemcitabine/nab-paclitaxel) and an immunotherapy (tislelizumab) for people with advanced pancreatic cancer. It may be an option if you have had little or no prior chemotherapy.
This trial tests a new combination of drugs (TQB2868 injection plus anlotinib capsules) compared to standard chemotherapy for people with pancreatic cancer that has spread to other parts of the body and has not been treated before.
This Phase 2 study tests a combination of medicines (including valproic acid and a statin) along with standard chemotherapy for people with newly diagnosed metastatic pancreatic cancer. The goal is to improve cancer control before any prior pancreatic cancer treatments and to see how well the medicines work and are tolerated.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.